文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌小鼠模型:基于分子亚型的临床转化关键考量

Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes.
PubMed 文献 · Eur Urol Oncol · 2018-09-13

本文基于PubMed 2000年1月至2018年2月的文献,从分子亚型角度综述肌层浸润性膀胱癌(MIBC)小鼠模型的优势、局限及转化应用。按建立技术分类后指出,异种移植和同种移植模型中接种细胞和部位决定分子亚型,自体模型可产生基底鳞状和管腔亚型但需进一步分子表征。这些模型是可再现MIBC分子复杂性并支持新治疗开发的多功能工具。

要点

  • 异种移植模型中接种细胞和接种部位是分子亚型的主要决定因素。
  • 同种移植模型能更真实地重建相关基质和免疫特征。
  • 自体模型可产生基底鳞状和管腔亚型,但需进一步分子表征。

核心结论

  • 已识别具有不同亚型特征的临床前MIBC模型并评估其前景和当前局限。
  • 这些模型是可再现MIBC分子复杂性并支持新治疗开发的多功能工具。

研究设计与样本

  • 基于PubMed 2000年1月至2018年2月发表文献的综述。
  • 按建立模型所用技术对MIBC小鼠模型进行分类。

主要发现

  • 异种移植和同种移植模型中,接种细胞和接种部位是分子亚型的主要决定因素。
  • 异种移植模型所用细胞系可覆盖大部分基底鳞状和管腔亚型。
  • 同种移植模型提供更真实的环境以重建相关基质和免疫特征。
  • 使用遗传和/或化学刺激诱导疾病进展的自体模型也可产生基底鳞状和管腔亚型,但需进一步分子表征,因此这些模型可能引入其他突变变异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 自体模型需进一步分子表征,因为这些模型可能引入其他突变变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In the past few years, research has suggested that molecular subtypes in muscle-invasive bladder cancer (MIBC) may be exploited to accelerate developments in clinical disease management and novel therapeutics. OBJECTIVE: To review MIBC mouse models from a molecular subtype perspective, their advantages and limitations, and their applications in translational medicine, based on a PubMed search for publications from January 2000 to February 2018. EVIDENCE ACQUISITION: Publications relevant to MIBC mouse models and their molecular subtypes were identified in a literature review. EVIDENCE SYNTHESIS: We classified the models according to the technique used for their establishment. For xenotransplant and allograft models, the inoculated cells and inoculated locations are the major determinants of molecular subtypes. Although the cell lines used in xenotransplant models can cover most of the basal-squamous and luminal subtypes, allograft models offer a more realistic environment in which to reconstruct aspects of the associated stromal and immune features. Autochthonous models, using genetic and/or chemical stimuli to induce disease progression, can also generate models with basal-squamous and luminal subtypes, but further molecular characterisation is needed since other mutational variants may be introduced in these models. CONCLUSIONS: We identified preclinical MIBC models with different subtype specifications and assessed their promise and current limitations. These models are versatile tools that can reproduce the molecular complexity of MIBC and support novel therapeutic development. PATIENT SUMMARY: Understanding which models of muscle-invasive bladder cancer most accurately represent the clinical situation is important for the development of novel drugs and disease management strategies. We review the different models currently available and their relevance to different clinical subtypes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ruan JL, Hsu JW, Browning RJ, et al. Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes. Eur Urol Oncol. 2018. PMID: 31200837. doi:10.1016/j.euo.2018.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。